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1. Introduction 
Acute myeloid leukemia (AML) is a broad range of disorders that are all characterized by a 
block in the differentiation and by uncontrolled proliferation of hematopoietic progenitor 
cells. AML is the most frequent hematological malignancy in adults, with an annual 
incidence of three to four cases per 100 000 individuals. Specific recurrent chromosomal 
abnormalities can be identified in approximately 55% of cases by cytogenetic analysis. These 
detected chromosomal aberrations are the most important tool to classify patients at their 
initial diagnosis and to divide them into favorable, intermediate and unfavorable 
subgroups. The age of the patient is also an important prognostic factor (Juliusson et al., 
2009; Szotkowski et al., 2010). However, approximately 45% of adult patients with AML 
have normal karyotype (cytogenetically normal /CN/-AML patients) and are usually 
classified as an intermediate risk group (Mrozek et al., 2007; Smith et al., 2011). These 
patients have a 5-year overall survival rate between 24% and 42%, but clinical outcome may 
vary greatly.  
The prognosis of AML with normal cytogenetics may be further subdivided based on 
genetic lesions. Even though a growing number of genetic lesions have been identified in 
CN-AML, about 25% CN-AML patients do not carry any of the currently known mutations. 
Therefore, many research groups conducted retrospective studies to find some candidate 
molecular markers that could identify good and poor risk AML patients with normal 
karyotype. In recent years, a number of gene mutations (NPM1 /nucleophosmin/, FLT3 
/Fms-like tyrosine kinase 3/, MLL-PTD /mixed lineage leukemia-partial tandem 
duplications/, C/EBP┙ /CCAAT/enhancer-binding protein alpha/CEBPA/, WT1 /Wilms 
tumor 1/, DNMT3A /DNA methyltransferase 3A/, IDH1 and IDH2 /isocitrate 
dehydrogenase/, CBL /Casitas B-lineage lymphoma/and others), as well as deregulated 
expression of genes (BAALC /brain and acute leukemia cytoplasmic/, ERG /ETS-related 
gene/, MN1 /meningioma 1/, EVI1 /ecotropic virus integration 1/, AF1q /ALL1-fused 
gene chromosome 1q/, PRAME /preferentially expressed antigen in melanoma/, WT1) 
have been found and further molecular markers (gene expression profiles and microRNA 
expression signatures) are studied and incorporated into clinical practice (Baldus & 
Bullinger, 2008; Bullinger & Valk, 2005; Bullinger 2006;  Kohlmann et al, 2010; Marcucci et 
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al., 2009, 2011a,b; Motyckova & Stone, 2010; Ramsingh et al., 2010; Schlenk et al., 2008; 
Wouters et al., 2009). It is necessary to improve current classification systems in order to 
reflect better the molecular heterogeneity of CN-AML (Döhner et al., 2010; Vardiman et al., 
2009).  
In addition, some of the genetic abnormalities have also been found to be useful for minimal 
residual disease (MRD) monitoring and as potential therapeutic targets in the development 
of new agents for AML therapy. The aim of monitoring of MRD is the identification of cases 
with a very high risk of relapse who then can be treated much earlier and more effectively 
(Jaeger & Kainz, 2003; Schnittger et al., 2009; Shook et al., 2009).   
Knowing the status of FLT-3 and other molecular markers (mutations and gene expression 
described above together with gene expression profiling) in CN-AML patients has not only 
prognostic significance but is important in the treatment based on these molecular markers. 
For example, patients with FLT3-ITD (an internal tandem duplication of the FLT3 receptor 
tyrosine kinase gene), who are not candidates for induction therapy and allogeneic stem cell 
transplantation may respond to an FLT3 inhibitor used in combination with chemotherapy 
or without chemotherapy. Deregulation of microRNA (miR) in CN-AML patients may act as 
complementary hit in the multisteps mechanism of leukemogenesis and has been not only 
used to identify subsets of  CN-AML patients  with diversified outcome but  will certainly 
play a role in the future of treatment in  new therapeutic strategies.  Thus, miR expression 
profiling has diagnostic and prognostic significance.  
2. Methods for the detection of gene mutations and expression 
2.1 Sample material 
After informed consent patient- or healthy individual-derived mononuclear cells were 
isolated from bone marrow (BM) or peripheral blood cells by a ficoll  (for example Ficoll-
Paque PLUS, GE Healthcare Bio-Sciences AB, Uppsala, Sweden) density gradient 
centrifugation. Total RNA and genomic DNA were isolated. Yield and quality of the RNA 
were measured by spectrophotometric analysis. Each sample was assessed for the integrity 
of RNA by discrimination of 18S and 28 S ribosomal RNA on 1% agarose gels using 
ethidium bromide for visualization. Complementary DNA was synthetised from total RNA 
using  reverse transcriptase (for example SuperScript II reverse transcriptase (Invitrogen 
Corporation, Carlsbad, CA, USA). 
2.2 Detection of gene mutations 
Most mutation detection methods use PCR (polymerase chain reaction) to amplify the 
region of DNA of interest. Mutant DNA has a different secondary structure (conformation) 
compared with that of the normal DNA. Frequently, this difference in conformation results 
in altered gel electrophoresis mobility of the mutant DNA species. Single-strand 
conformation polymorphism (SSCP) method (Orita et al., 1989; Perry, 1999) based on this 
conformation change is a fast and efficient method for detecting many types of aberrations, 
including point mutations, insertions, deletions and rearrangements (Frayling, 2002; Kutach 
et al., 1999). SSCP has the sensitivity to identify single nucleotide changes in the DNA 
sequence. Thermally denaturated DNA is electrophoresed and mutation is detected as 
aberrantly migrating bands on the electrophoresis gel. Analyzed PCR products must be less 
than 300 bp and preferably less than 200 bp in size because the method is increasingly 
inefficient with increasing size of the PCR product. Another technique, related to SSCP is 
www.intechopen.com
Molecular Markers for Risk Stratification in 
Adult Acute Myeloid Leukemia with Normal Cytogenetics 
 
97 
DNA heteroduplex analysis (Frayling, 2002). Both SSCP and heteroduplex analysis can be 
carried on fluorescent DNA analysers at a controlled temperature. The related techniques 
DGGE (denaturing gradient gel electrophoresis) and TGGE (thermal gradient gel 
electrophoresis) arevery efficient, but they require specially designed PCR primers of 
increased length (Frayling, 2002). Sequencing of the mutated PCR product is almost 
universally carried out using dideoxy terminator chemistry .   
High resolution melting  (HRM) analysis is rapidly becoming the most important initial 
screen procedure for potential mutations (Razga et al., 2009; Tan et al., 2008; Vaughn & 
Elenitoba-Johnson, 2004; Wittwer, 2009).  PCR amplification and subsequent HRM analysis 
are sequentially performed in the one tube.  HRM is more simple than denaturing high – 
performance liquid chromatography (DHPLC), which can be also used after PCR 
amplification for mutation detection (Bianchini et al., 2003; Kosaki et al., 2005; Roti et al., 
2006). Real-time PCR machine with HRM capability, for example LightCycler 480 High – 
Resolution Melting Master (Roche Diagnostics) has been successfully used for PCR 
amplification and HRM analysis. PCR reactions must be designed in the maner to avoid 
primer dimers and non-specific amplification. DNA has to be prepared in a uniform fashion 
to avoid variation in salt concentration with effect on the melting. HRM significantly 
reduces the quantity of samples that is necessary for sequencing with consequent reduction 
of cost and labour and enables rapid detection of mutations.  The melting curves are 
normalized and temperature shifted to allow samples to be directly compared. Difference 
plots are generated by selecting a negative (nonmutated) control as the base-line and the 
fluorescence of all other samples is plotted relative  to this negative control. Significant  
differences in fluorescence are indicative of mutations which must be detected by 
sequencing. Noordermer et al. (2010) used HRM curve analysis for rapid identification of 
IDH1 and IDH2 mutations in AML.  
Currently, identification of mutations by PCR and direct nucleotide sequencing is used as 
the gold standard.  The great progress  was achieved in DNA sequencing technology in last 
ten years after the end of Human Genome Project (Mardis, 2011).  The Roche/454, Life 
Technologies SOliD and Illumina instruments have been used to sequence the complete 
tumor and normal genomes in order to identify mutations that alter the protein-coding 
genes. Whole genome sequencing is now possible at a reasonable cost  per tumor and 
normal genome of around $ 30,000 and can be completed in about 8 days. A pilot study of 
high-throughput, sequence-based mutational profiling of primary AML cell genomes was 
done eight years ago (Ley et al., 2003). Whole genomic DNA sequencing of  a cytogenetically 
normal FAB M1 AML patient was done three years ago and discovered ten genes with 
acquired mutations (Ley et al., 2008).  Eight novel somatic mutations were described in 
genes not previously implicated in AML pathogenesis. Two well-known AML-associated 
mutations, including FLT3-ITD, which constitutively activates kinase signaling and a four 
base insertion in exon 12 of the NPM1 gene were also detected. Mardis et al. (2009) 
identified twelve somatic mutations within the coding sequences of genes and 52 somatic 
point mutations in conserved or regulatory portions of the AML genome. Two known 
mutations in NRAS and NPM1 and ten novel mutations were detected. One of these 
mutations (missense R132C mutation in IDH1 gene) is today included in many mutational 
screening of AML patients. The more efficient, faster and cheaper approach will be 
sequencing of coding regions (the cDNA transcriptome) but the abundance of transripts can 
vary and some mutations can be missed (Greif et al., 2011). The size of the transcriptome is 
about  ten times shorter than a diploid human genome  
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Mutations in molecular markers can be present in low abundance within a high background 
of wild type sequence that may only differ from mutant at a single nucleotide. Several 
methods exist for detection of somatic mutations by real-time PCR. These methods include 
use of allele-specific competitive blocker PCR (Orou et al., 1995),  blocker-PCR (Seyama et 
al., 1992), real-time genotyping with locked nucleic acids (Ugozzoli et al., 2004), the 
amplification refractory mutation system (Newton et al., 1989), and fluorescent amplicon 
generation as a novel real-time PCR technology (Amicarelli et al., 2007). 
Mutated NPM1 is localised in the cytoplasm and not in the nucleus (Bolli et al., 2007; Falini 
et al., 2006; Liso et al., 2008; Oelschlaegel et al., 2010). Immunohistochemical detection of 
cytoplasmic nucleophosmin is performed with monoclonal antibody or by Western blotting  
(Falini et al., 2006, 2009, 2010a; Martelli et al. 2008). 
2.3 Technique of real-time PCR (RQ-PCR) for marker gene expression evaluation 
RQ-PCR permits accurate quantification of PCR products during the exponential phase of 
the PCR amplification process. Three main types of this analysis are used: (1) RQ-PCR using 
the hydrolysis probe format (“TaqMan probe“);  (2)  RQ-PCR using the hybridization probe 
format;  and (3)  RQ-PCR using SYBR Green Dye (Kern et al., 2005).  Analysis with TaqMan 
probe uses 5´-3´ exonuclease activity of the Thermus aquaticus (Taq) polymerase to detect and 
quantify the PCR product. The hydrolysis probe  is positioned within the target sequence 
and is conjugated with a reporter fluorochrome at the 5´ end and a quencher fluorochrome 
at the 3´ end. The quencher avoids the reporter from emission of a fluorescence signal as 
long as the probe is intact and both fluorochromes are in the close proximity. Upon 
amplification of the target sequence, the hydrolysis probe is displaced from the DNA strand 
by the Taq polymerase and subsequently hydrolysed by the 5´-3´ exonuclease activity of the 
Taq polymerase. This results in displacement of of the reporter from the quencher and the 
fluorescence of the reporter becomes detectable. 
Generally two quantification types (relative or absolute) in RQ-PCR are possible.  A relative 
quantification based on relative expression of a target gene versus a reference gene is 
adequate for the most purposes. For absolute quantification, based either on an internal or 
an external calibration curve (Bustin et al., 2005; Ptaffl, 2001, Ptaffl et al. 2002), the 
methodology must be highly validated and the identical LightCycler PCR amplification 
efficiencies for standard material and target cDNA must be confirmed. 
2.4 Genes and microRNAs microarrays 
RNA was extracted using Trizol reagent  and processed for Affymetrix U133 plus 2.0 
GeneChip (Affymetrix, Santa Clara, CA) hybridizations. Briefly, from 5 µg total RNA, 
double-stranded cDNA was prepared with the use of the T7-Oligo(dT) primer (Affymetrix). 
In vitro transcription for amplification and biotinylation of the RNA transcript was 
performed with the BioArray HighYield RNA Transcript Labeling Kit (T7; Enzo Life Science, 
Farmingdale, NY). Biotin-cRNA (10 µg) was fragmented and hybridized onto the U133 plus 
2.0 GeneChip for 16 hours at 45°C and labelled with Cy-3-streptavidin conjugate according 
to manufacturer protocols. Scanned images were converted to CEL files using GCOS 
software (Affymetrix). For the miRNA microarray chips, biotinylated first-strand cDNA was 
synthesized in reverse transcription from 2.5 to 5.0 µg total RNA using biotin-labeled 
random octamer oligo primer from pretreatment BM and blood mononuclear cell samples 
and hybridized to miRNA microarray chip KCC/TJU containing 368 probes in triplicate, 
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corresponding to 245 human miRNA genes. After hybridization for 18 hours at 25°C and 
washing, direct detection of the biotin-containing transcripts by streptavidin-Alexa647 
conjugate was done and processed slides were scanned. Expression profiles were analyzed 
in GENESPRING software(Silicon Genetics, Redwood City, CA). 
3. Mutations in the molecular markers 
3.1 Mutations in the NPM1 gene 
Nucleophosmin (NPM1, also called nucleolar protein B23, numatrin or NO38) is a 
multifunctional phosphoprotein which contains 294 amino acids (Okuwaki et al., 2006). 
NPM1 is one of the three nucleophosmin isoforms which are generated through alternative 
splicing. NPM1 resides predominantly in the nucleoli, but also continuously shuttles 
between nucleus and cytoplasm (Frehlick et al., 2006).  The NPM1 gene is located on 
chromosome 5q35 in humans and is composed of 12 exons (Chan et al., 1989).  NPM1 is 
essential for processing and transportation of ribosomal RNA and proteins, molecular 
chaperoning, and regulation of the stability  of tumor suppressors, such as p53 and ARF 
(Borer et al., 1989; Colombo et al., 2002; Enomoto et al., 2006; Herrera et al., 1995; Li & Hann, 
2009; Maggi et al., 2008; Savkur & Olson, 1998; Yu et al., 2006). The ARF tumor suppressor is 
a protein that is transcribed from an alternate reading frame of the  inhibitor of cyclin-
dependent kinase CDK4. NPM1 can affect DNA replication, repair and transcription by 
interacting with the components of chromatin such as histones and chromatin remodeling 
proteins  (Amin et al., 2008a,b; Angelov et al., 2006; Koike et al., 2010). NPM1 plays 
important roles in cell cycle (Ugrinova et al., 2007; Xiao et al., 2009). NPM1 may 
preferentially promote ribosome biogenesis in G1, facilitate DNA replication during S-phase 
while supporting chromosome segregation in mitosis (Hisaoka et al., 2010). 
Almost 40% of  CN-AML patients have mutations in exon 12 of the NPM1 gene which result 
in loss of tryptophan residues normally required for NPM1 binding to the nucleoli and in 
the generation of an additional nuclear export signal motif at the C-terminus of NPM1 
which causes its abnormal cytoplasmic localization (Bolli et al., 2007; Falini et al., 2006; Liso 
et al., 2008; Oelschlaegel et al., 2010). These mutations are the most common genetic 
alterations in adult CN-AML patients and are associated with female sex, higher white 
blood count, increased blast percentage, and low or absent CD34 expression. Cytoplasmic 
nucleophosmin leukemic mutant is also rarely generated by a exon-11 NPM1 mutation 
(Albiero et al., 2007). Acute myeloid leukemias with mutated NPM1 (NPM1c+)  have 
distinct characteristics, including a significant association with a normal karyotype, 
involvement of different hematopoietic lineages, a specific gene-expression profile and 
clinically, a better response to induction therapy and a favorable prognosis (Meani & 
Alcalay, 2009; Rau & Brown, 2009, Falini et al., 2010). NPM1c+ maintains the capacity of 
wild-type NPM to interact with a variety of cellular proteins, and impairs their activity by 
delocalizing them to the cytoplasm. NPM1c+  specifically inhibits the activities of the cell-
death proteases, caspase-6 and -8, through direct interaction with their cleaved, active 
forms, but not the immature procaspases. NPM1c+ not only affords protection from death 
ligand-induced cell death but also suppresses caspase-6/-8-mediated myeloid 
differentiation (Leong et al., 2010). 
After the discovery of NPM1-mutated AML in 2005 and its subsequent inclusion as a 
provisional entity in the 2008 World Health Organization classification of myeloid 
neoplasms, several controversial issues remained to be clarified (Falini, 2011). It was unclear 
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whether the NPM1 mutation was a primary genetic lesion and whether additional 
chromosomal aberrations and multilineage dysplasia (MLD) had any impact on the biologic 
and prognostic features of NPM1-mutated AML. Moreover, it was uncertain how to classify 
AML patients who were double-mutated for NPM1 and CEBPA. Recent studies have shown 
that: (1) the NPM1 mutant perturbs hemopoiesis in experimental models; (2) leukemic stem 
cells from NPM1-mutated AML patients carry the mutation; and (3) the NPM1 mutation is 
usually mutually exclusive of biallelic CEPBA mutations. Moreover, the biologic and clinical 
features of NPM1-mutated AML do not seem to be significantly influenced by concomitant 
chromosomal aberrations or multilineage dysplasia. NPM1-mutated AML with and without 
MLD showed overlapping immunophenotype (CD34 negativity) and gene expression 
profile (CD34 down-regulation, homeobox (HOX) genes up-regulation). Altogether, these 
pieces of evidence point to NPM1-mutated AML as a founder genetic event that defines a 
distinct leukemia entity accounting for approximately one-third of all AML. Distinctive gene 
expression and microRNA signatures were found associated with AML bearing cytoplasmic 
mutated NPM1 (Becker et al., 2010; Garzon et al., 2008, Verhaak et al., 2005). 
Approximately 40% of patients with NPM1 mutations also carry FLT3 internal tandem 
duplications (FLT3-ITD). Patients with NPM1 mutations, who did not also have FLT3 
mutation have generally more favorable prognosis (Gale et al., 2008; Scholl et al., 2008; Luo 
et al., 2009).  The favourable prognosis of NPM1-mutated/FLT3-ITD negative patients might 
be explained by a higher bax/bcl-2 ratio (Del Poeta et al., 2010). These patients respond to 
induction therapy and stay in remission more likely. These patients may be exempted from 
allogenic hematopoietic stem cell transplantation during the first complete remission 
because their outcome after conventional consolidation chemotherapy is the same as after 
allogenic transplantation. However, patients with NPM1 mutations who also carry FLT3 
mutation have bad prognosis. 
Moreower, NPM1 mutations due to their frequency and stability, may be used for minimal 
residual disease monitoring in AML patients with a normal karyotype (Bacher et al., 2009; 
Schnittger et al., 2009; Dvorakova et al., 2010).  
3.2 FLT3 mutations 
The feline c-fms proto-oncogene product is a 170 kd glycoprotein with associated tyrosine 
kinase activity. Fms-like tyrosine kinase 3 (FLT3)  and its ligand (FL) are important in 
hematopoietic progenitor cell proliferation and differentiation (Gilliland & Griffin, 2002).  As 
a result of ligand binding, FLT3 receptor on the cell surface of hematopoietic progenitors 
dimerizes, resulting in activation of its tyrosine kinase domain, receptor 
autophosphorylation, and recruitment of downstream signaling molecules such as signal 
transducer and activator of transcription 5a (STAT5a), and the MAPK (mitogen activated  
protein kinases) pathways leading to proliferative and pro-survival effects.   
Internal tandem duplication (ITD) of base pairs within the juxtamembrane coding portion or 
point mutations in the second kinase domain occur in approximately 30% of patients with 
newly diagnosed AML and  result in constitutive activation of the  FLT3 gene on 
chromosome 13q12 ( Nakao et al., 1996; Naoe & Kiyoi, 2004; Yamamoto et al., 2001). FLT3 
mutations in the case of ITDs are associated with chemoresistance in the leukemic stem cells, 
shorter disease-free survival and overall survival and higher rate of relapse (Frohling et al., 
2002; Ravandi et al., 2010; Whitman et al., 2010). Specific gene expression signature 
associated with FLT3-ITD was described (Bullinger et al., 2008; Whitman et al., 2010). 
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Overexpression  of FLT3, homeobox genes  and immunotherapeutics targets and decreased 
expression of erythropoiesis-associated genes is connected with FLT3-ITD. The prognostic 
significance of FLT3 point mutations is less clear with conflicting results (Mead et al., 2008). 
In clinical practice, a frequent approach to patients with poor prognostic AML is to offer 
allogenic stem cell transplantation (SCT). Gale et al. (2005) found no benefit from any form 
of transplantation consolidation for patients with FLT3-ITD. Several inhibitors of FLT3 have 
entered clinical trials and are studied alone or mainly in combination with chemotherapy 
(Kindler et al., 2010; Small, 2008; Weisberg et al., 2009; Wiernik, 2010). 
3.3 CCAAT/enhancer binding protein alpha (CEBPA) mutations 
The CCAAT/enhancer binding protein alpha (C/EBPǂ) is the founding member of a family 
of related leucine zipper transcription factors that play important roles in myeloid 
differentiation (Friedman et al., 2007; Keeshan et al., 2003; Pabst & Mueller, 2007; Suh et al, 
2006; Tenen et al. 1997). Members of this family consist of N-terminal transactivation 
domains, a DNA-binding basic domain, and a C-terminal leucine rich dimerization region 
(Fig. 1). 
 
 
Fig. 1. The location of functional domains within the C/EBPǂ protein. Numbers directly 
above the schema indicate the amino acids of the human C/EBPǂ. Numbers directly under 
the schema indicate nucleotides (GenBank Accession No. NM_004364.2). The full-length 42 
kDa form of C/EBPǂ protein and the shorter, dominant negative 30 kDa form of this protein 
are also shown. 
The dimerization domain, known as  ”leucine zipper“, contains leucine repeats that 
intercalate with leucine repeats of the dimer partner forming a coiled coil of ǂ helices in 
parallel orientation. C/EBPǂ mRNA is translated into two major proteins, C/EBPǂ p42 (42 
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kDa) and C/EBPǂ p30 (30 kDa) by ribosomal scanning mechanism in which a fraction of 
ribosomes ignore the first two AUG codons and initiate translation at the third AUG codon 
located 357 nucleotides downstream of the first one (Fig. 1). The 30 kDa protein lacks the 
transactivating domain TAD1 (Fig. 1) and was shown to inhibit DNA binding and 
transactivation by C/EBPǂ p42 (Pabst et al., 2001). C/EBPǂ p30 fails to induce myeloid 
differentiation (D'Alo' et al., 2003; Friedman et al., 2007). Targeted inactivation of C/EBPǂ in 
mice demonstrates its importance in the proper development and function of liver, adipose 
tissue, lung and hematopoietic tissues (Flodby et al., 2006; Wang et al., 1995; Zhang et al., 
1997). C/EBPǂ is highly expressed in these differentiated tissues where it controls 
differentiation-dependent gene expression and inhibits cell proliferation (Fuchs 2007).  
Learning more about the precise molecular functions of the C/EBPǂ protein and how these 
are affected by leukemogenic mutations should lead to an improved understanding of the 
cellular functions that are disrupted in patients with AML.  
CEBPA mutations were found in 10-19% of  CN-AML patients (Gombart et al., 2002; 
Fröhling et al., 2004; Fuchs et al., 2008, 2009; Lin et al., 2005; Pabst et al., 2001; Preudhomme 
et al., 2002). Two kinds of mutations were mainly described: 1) truncating, frameshift 
mutations occuring near the N-terminus in one of the two transcription activations domais 
(TAD1 and TAD2) on one allele and 2) in-frame insertions or deletions clustering within the 
C-terminal basic domain- leucine zipper (DBD and ZIP) on the other allele. Often, CN-AML 
patients with CEBPA mutations belong to FAB (French –American –British) subtypes M1 or 
M2 and have one mutation towards N-end  and one  towards C-end but other cases of 
mutations were also detected. Kato et al. (2011) showed that a mutation of CEBPA in one 
allele was observed in AML after MDS while the two alleles are mutated in de novo AML. 
Favourable impact of CEBPA mutations was mainly observed in patients with biallelic 
mutation and with lack of FLT3-ITD (Dufour et al., 2010; Hou et al., 2009; Pabst et al., 2009; 
Radomska et al. 2006; Taskesen et al., 2011; Wouters et al., 2009).  
3.4 Partial tandem duplications of the MLL gene 
The mixed lineage leukemia gene (MLL, also known as ALL-1 or HRX), located on 
chromosome 11q23,  encodes a histone methyltransferase and is frequently rearranged in 
AML. Wild-type MLL is schematicly presented in Fig. 2. To date, MLL has been found in 
more than sixty different translocations with different fusion partners (Basecke et al., 2006; 
De Braekeleer et al., 2005). Partial tandem duplications of the MLL gene were first observed 
in CN-AML by Caligury et al., 1994. These duplications consist of an in-frame repetition of 
MLL exons in a 5´-3´ direction and lead to the change of the resulting transcript and protein. 
MLL-PTD are named according to the fused exons (mainly e9/e3, e10/e3, e11/e3).  
MLL-PTD are detectable in 5%-11% of patients with CN-AML (Döhner et al., 2002; Döhner & 
Döhner 2008; Schnittger  et al., 2000; Steudel et al., 2003). MLL-PTD have been found also in 
peripheral blood and bone marrow samples of healthy adults. However in contrast to the 
MLL-PTD in AML, MLL-PTD in healthy adults had often unusual exon fusions and showed 
an ladder on gel electrophoresis after the nested RT-PCR (Basecke et al., 2006; Marcucci et 
al., 1998; Schnittger  et al., 1998). MLL-PTD cooperate with silencing of the MLL wild-type 
allele by epigenetic mechanisms. MLL-PTD contribute to leukemogenesis through 
hypermethylation of DNA and epigenetic silencing of tumor suppressor genes (Dorrance et 
al., 2006; Whitman et al., 2008a). Inhibitors of  DNA methyltransferase and histone acetylase 
inhibitors and their combination can re-activate the wild-type allele in MLL-PTD-positive 
blasts (Whitman et al., 2005). 
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Fig. 2. Exon-intron structure of the wild-type MLL gene involved in tandem and nontandem 
duplications. The nomenclature is different in various studies (Nilson et al., 1996; Strout et 
al., 1998, Šárová et al., 2009). The MLL gene as a whole contains 36 or 37 exons according to 
the different nomenclatures and the resulting product of its expression contains 3969 amino 
acids. In the case of  MLL-PTD e9/e3 are exons and introns between exons 3 and 9 inserted 
between exons  9 and 10 of the wild-type MLL and are duplicated by this way (the fusion of 
introns 2 and 9). 
MLL-PTD are associated with shorter duration of the complete remission, shorter relapse-
free survival and event-free survival, but  MLL-PTD have no effect on overall survival 
Döhner & Döhner. 
3.5 Wilms´ tumor 1 (WT1) mutations 
The Wilms tumor  1 (WT1) gene is located on chromosome 11p13 and encodes a zinc-finger  
transcriptional regulator that can function as tumor suppressor in patients with the WAGR 
(Wilms´ tumor predisposition, aniridia, genitourinary abnormalities, and mental 
retardation) tumor predisposition syndrome (Haber et al., 1990) and as an oncogene in 
various leukemias, as well as other cancers (Ariyaratana & Loeb, 2007; King-Underwood et 
al., 1996; Miwa et al., 1992; Yang et al., 2007). Mutations in WT1 gene were found in 
approximately 10% of AML patients (Hou et al., 2010; Gaidzik et al., 2009; Owen et al., 2010; 
Paschka et al., 2008; Virappane et al. 2008). Mutations are mainly localized in zinc-finger 
domains in exons 7 and 9 but can be also found in exons 1,2,3, and 8. The truncated WT1 
protein is the result of frameshift mutations in exon 7. Truncated WT1 is without nuclear 
localization signal and does not bind to other interacting proteins as p53 and its homologue 
p73. Frameshift mutations in exon 9 are less frequent but there are also missense mutations. 
WT1 mutations have been reported as an adverse prognostic factor in adult CN-AML and 
independently predict for poor outcome  (Hou et al., 2010; Gaidzik et al., 2009; Owen et al., 
2010; Paschka et al., 2008; Renneville et al., 2009; Virappane et al. 2008). WT1 mutations lead 
to inferior rate of complete remission, higher incidence of relapse abd to shorter relapse-free 
survival and overall survival. A recent study demonstrated  that a single nucleotide 
polymorphism SNP rs16754 in the WT1 mutational hotspot predicted favorable outcome in 
CN-AML (Damm et al. 2010). 
3.6 Isocitrate dehydrogenase 1 and 2 (IDH1, IDH2) gene mutations 
Mardis et al. (2009) found recurring mutations in codon 132 of the IDH1 gene by sequencing 
a whole AML genome as described in paragraph 2.2. The protein encoded by this gene is the 
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enzyme that catalyzes the oxidative carboxylation of isocitrate to ǂ-ketoglutarate leading to 
nicotinamide adenine dinucleotide phosphate production in Krebs cycle and was found in 
the cytoplasm and peroxisomes (Geisbrecht & Gould, 1999). Three classes of IDH 
isoenzymes exist in mammalian cells (two forms of mitochondrial IDH and cytosolic IDH). 
IDH1 gene is localized to chromosome band 2q33.3 and IDH2 gene to chromosome band 
15q26.1 (Narahara et al.,1985; Oh et al.,1996). IDH2 encodes the mitochondrial isoform that 
uses nicotinamide adenine dinucleotide phosphate as a cofactor. The same cofactor is also 
used by IDH1. 
Most cancer-associated enzyme mutations result in constitutive activation or inactivation of 
the mutated enzyme. IDH1 and IDH2 mutations result in the new enzyme activity, 
production of 2-hydroxyglutarate, not shared by wild type enzymes (Ward et al., 2010). This 
accumulation of  2-hydroxyglutarate induces global DNA hypermethylation, disrupts TET2 
function because this enzyme is ǂ-ketoglutarate-dependent, and impairs hematopoietic 
differentiation (Figueroa et al., 2010). TET2  is a homolog of the gene originally discovered at 
the chromosome ten-eleven translocation (TET) site in a subset of patients with AML. TET2 
catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine, suggesting a 
potential role for TET proteins in epigenetic regulation. Blocking the accumulation of  2-
hydroxyglutarate  through the inhibition of mutant IDH enzymes could represent a 
therapeutic target (Dang et al. , 2010; Cazola 2010). 
IDH1 mutations at codon R132 occur in CN-AML patients with a frequency of 5.5% to 11% 
(Boissel et al., 2010; Gross et al., 2010; Patel et al., 2011; Schnittger et al., 2010; Wagner et al., 
2010). A strong association between IDH1 mutations and the NPM1 mutation and M1 FAB 
subtype was observed. On the other hand, IDH1 mutations are inversely associated with the 
M4 FAB subtype and expression of HLA-DR, CD13 and CD14 antigens. The prognostic 
impact of  IDH1 mutations in CN-AML is associated with a higher risk of relapse and a 
shorter overall survival (Abbas et al., 2010; Boissel et al., 2010; Marcucci et al., 2010; Paschka 
et al., 2010; Schnittger et al., 2010). Others (Chou et al., 2010a; Patel et al., 2011; Wagner et al., 
2010), however, found no significant impact of IDH1 mutations on CN-AML patients 
outcome. IDH2 mutations in exon 4, including mainly codon R140 and in rare cases codon 
R172, had no prognostic impact (Thol et al., 2010). Recent study of Chou et al. (2011) showed 
high stability of  IDH2 mutations during disease evolution and their connection with 
favorable prognosis. Contrary to this observation, Boissel et al. (2010) found IDH2 mutations 
independently associated with a higher risk of relapse and shorter overall survival. The 
prognostic impact of  IDH1 mutations and IDH2 mutations needs further study as very 
controversial results were obtained. Green et al. (2010) observed no difference in outcome 
between IDH1 mutated and nonmutated patients when the results were stratified by an 
NPM1 mutation status but an adverse outcome for IDH1 mutated  patients when the results 
were correlated with FLT3-ITD mutation. 
3.7 Mutations in gene for DNA methyltransferase 3A (DNMT3A) 
About 22% of CN-AML patients have DNMT3A mutations. The most common DNMT3A 
mutation affects amino acid R882 but other parts of DNMT3A gene are also affected by 
mutations  in CN-AML patients (Ley et al., 2010). Aberrant DNA methylation contributes to 
the pathogenesis of cancer (Rodríguez-Paredes & Esteller 2011; Taberlay & Jones, 2011; 
Watanabe & Maekawa, 2010). Clusters of CpG dinucleotides in promoters of tumor-
supppressor genes are hypermethylated in cancer genomes and this hypermethylation 
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results in reduced expression of the downstream gene. However, inhibition of DNA 
methyltransferases is only one potential mechanism of function of demethylating agents (5-
azacytidine and decitabine). DNMT3A mutations do not change 5-methylcytosine content in 
AML genomes but are associated with poor survival. DNMT3A mutations are in many cases 
found together with FLT3 mutations, NPM1 mutations and IDH1 mutations. All these 
combinations of mutations have a significantly worse outcome.    
3.8 RAS mutations in CN-AML 
Ras-signaling cascade contributes to the molecular pathogenesis of myeloproliferative 
disorders (Chan et al., 2004). Ras oncogenes (small GTPases) regulate mechanism of 
proliferation, differentiation, and apoptosis. NRAS (neuroblastoma RAS) mutations  were 
detected in 9% of adult CN-AML patients and 14% of CN-AML patients younger than 56 or 
60 years (Bacher et al., 2006; Bowen et al., 2005). There was no prognostic impact of these 
mutations in most studies (Gaidzik & Döhner, 2008; Ritter et al., 2004; Schlenk & Döhner, 
2009). Mutations in other members of  Ras family are rare in CN-AML and there was also no 
consistent effect on prognosis but the presence of  Ras mutations appears to sentisize AML 
blasts  to high dose cytarabine in vivo (Motyckova & Stone 2010). 
3.9 Other gene mutations in CN-AML 
Mutations in RUNX1 have been shown in approximately 10%-13% of CN-AML (Döhner & 
Döhner, 2008, Tang et al., 2009). These mutations were positively associated with MLL-PTD 
and negatively associated with NPM1 and CEBPA mutations. They predict ed a lower 
complete remission rate and shorter disease-free and overall survival .   
TET2 (ten-eleven-translocation)  first described in 2008, include frameshift, nonsense and 
missense mutations lying across several of its 12 exons located on chromosome 4q24 (Abdel-
Wahab et al., 2009; Bacher et al., 2010; Mohr et al., 2011; Nibourel et al., 2010). The direct 
influence of  mutations in TET2 on patient survival in CN-AML  remains a disputable issue. 
TET2 mutations were revealed in 10%-25% of CN-AML patients. Abdel-Wahab et al. (2009) 
showed a decreased survival rate in mutated TET2 in comparison with wild-type TET2 
group of CN-AML. However, Nibourel et al. (2010) did not find significant impact of TET2 
mutation on clinical outcome of CN-AML patients but they observed mutated TET2 
strongly associated with mutated NPM1. Recently, Metzeler et al. (2011) have found TET2 
mutations in 23%of CN-AML patients and these mutations were associated with older age. 
In favorable–risk group of CN-AML patients with CEBPA mutation and/or  mutated NPM1 
without FLT3-ITD, TET2-mutated patients had shorter event-free survival, lower complete 
remission rate and shorter disease-free and overal survival. In CN-AML patients with 
intermediate risk with wild-type CEBPA and wild-type NPM1 without FLT3-ITD, TET2 
mutations were not associated with outcomes. 
CBL (Casitas B-cell lymphoma) mutations were identified in rare cases of CN-AML (Bacher 
et al., 2010; Makishima et al., 2009; Reindl et al., 2009). Cbl is E3 ubiquitin ligase involved in 
degradation of activated receptor tyrosine kinases, including Src kinases (Makishima et al., 
2009). Presence of these mutations was suggested  to be involved in aberrant FLT3 
expression. FLT3 ligand–dependent hyperproliferation of CBL mutant cells could be 
abrogated by treatment with the specific inhibitor, midostaurin (PKC412). 
Mutations in the additional sex comb-like 1 (ASXL1) gene were analyzed in exon 12 in CN-
AML patients and 8.9% mutations were detected (Chou et al., 2010b).  This mutation was 
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closely associated with older age, male sex, RUNX1 mutation and expression of human 
leukocyte-antigen-DR and CD34 (Chou et al., 2010b; Rocquain et al., 2010).  Association with 
FLT3-ITD, NPM1 mutation, WT1 mutation, and expression of CD33 and CD15 was not 
detected. ASXL1 mutated patients had a shorter overall survival than patients without this 
mutation, but  the mutation was not an independent adverse prognostic factor in 
multivariete analysis. 
Phosphoinositide phospholipase Cǃ1 (PI-PLC┚1) gene mutations are very rare in CN-AML  
(Damm et al., 2010). Follo et al. (2009) described greater representation of these mutations 
(monoallelic deletions) in AML and their association with a worse clinical outcome. 
4. Overexpression of marker genes with prognostic relevance 
Alterations in the expression of genes belonging to signal transduction pathways as well as 
transcription factors are known to play a  functional role in the pathogenesis of AML.  
Therefore, these marker genes are implicated in the process of leukemogenesis and their 
overexpression may be useful to predict outcome in CN-AML patients. 
4.1 WT1 gene expression 
The WT1 gene overexpression was found in several leukemias, including AML (Cilloni et 
al., 2009). WT1 mRNA levels in the peripheral blood can predict relapse after achieving 
complete remission, and its levels after consolidation therapy are closely correlated with 
disease-free and overall survival, and with early relapse (Cilloni et al., 2009; Gianfaldoni et 
al., 2010; Miyawaki et al., 2010). Monitoring of WT1 expression is significant predictor of 
relapse in AML patients after hematopoietic cell transplantation (Lange et al., 2011). 
4.2 BAALC (brain and acute leukemia, cytoplasmic) expression 
The BAALC gene, located on chromosome 8q22.3, is primarily expressed in neuroectoderm-
derived tissues and in hematopoietic precursors and encodes a protein with unknown 
function (Baldus et al., 2003, 2006; Langer et al., 2008; Santamaria et al., 2010). High level of 
BAALC expression showed a higher refractoriness to induction treatment , lower complete 
remission rate after salvage therapy and lower overall survival and relapse – free survival in 
intermediate-risk AML (Santamaria et al., 2010).  The BAALC expression is considered an 
independent prognostic factor in CN-AML. High BAALC expression was associated with 
FLT3-ITD, and high ERG expression in multivariable analysis (Baldus et al., 2006). High 
BAALC expression is also connected with overexpression of genes involved in drug 
resistance (MDR1)  and stem cell markers (CD133, CD34, KIT). In low BAALC expressers, 
genes associated with undifferentiated hematopoietic precursors and unfavorable outcome 
predictors were downregulated, while HOX–genes and HOX–gene-embedded-miR were 
upregulated (Schwind et al., 2010).  Global miR expression analysis did not reveal significant 
differences between different rate BAALC expression groups (Langer et al., 2008).  Inverse 
association between the expression of miR148a and BAALC was revealed. 
4.3 ERG (v-ets erythroblastosis virus E26 oncogene homolog) expression 
ETS-related gene (ERG), located at chromosome band 21q22, is downstream effector of 
signaling transduction pathways involved in the regulation of cell proliferation, 
differentiation, and apoptosis (Marcucci et al., 2005,2007; Mrózek et  al., 2007; Metzeler et al. 
2009, Schwind et al., 2010). CN-AML patients with overexpression of ERG have been 
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reported to have a poor clinical outcome. When combined with other known prognostic 
markers, ERG expression can improve the molecular risk-based stratification of patients 
with CN-AML. Low ERG expression is associated with downregulation of genes involved in 
the DNA-methylation machinery, upregulation of miR148a, which targets DNA 
methyltransferase 3B (DNMT3B) and with better outcome (Schwind et al., 2010).   
4.4 MN1 (meningioma 1) expression 
MN1 is located at 22q11 and its overexpression is associated with lower response rate after 
first course of induction therapy and poor clinical outcome for CN-AML patients. Moreover, 
high MN1 expression was connected with a higher relapse rate and worse relapse-free and 
overall survival (Grosveld, 2007; Heuser et al., 2006; Langer et al., 2009). MN1 expression 
levels were directly correlated with BAALC expression levels and with the expression of 
genes reported as associated with a BAALC expression signature, specifically with 
expression of CD34 and ABCB1 (MDR1) and several other genes (Langer et al., 2008, 2009). 
MN1 expression levels were negatively connected with expression of HOX genes and with 
NPM1 mutated CN-AML (Langer et al., 2009). MN1-associated miR-expression signature 
comprises 15 miR, expression of 8 miR (hsa-miR-126 family) was positively correlated and 
expression of 7 miR (hsa-miR-16, hsa-miR-19a and hsa-miR-20a, all members of miR-17-92 
polycistron) negatively correlated with MN1 expression (Langer et al., 2009). MN1 
overexpression confered resistance to the differentiation activity of all-trans-retinoic acid 
(ATRA) in AML (Heuser et al., 2007).   
4.5 EVI1 (ecotropic viral integration site 1) expression 
Human EVI1 is localized to chromosome 3 band q26, spans 60kb, and contains 16 exons 
(Goyama &Kurokawa, 2009). High EVI1 expression occurs in approximately 8% of patients 
with de novo AML (Barjesteh van Waalwijk van Doom-Khosrovani et al., 2003). High EVI1 
expression was observed not only in AML carrying the chromosome 3 abnormalities, but 
also in CN-AML (Gröschel et al., 2010; Lugthart et al., 2008; Santamaria et al., 2009) and is in 
both groups connected with poor treatment response.  
4.6 Other molecular marker genes expression 
The PRAME (preferentially expressed antigen of melanoma) gene was shown to be 
expressed in high levels in AML. PRAME mRNA was observed in about one-third of AML 
cases and there was a good correlation between PRAME mRNA level and hematological 
remission and relapse. It may be also useful marker to detect minimal residual disease after 
allogenic transplantation (Paydas et al., 2005; Qin et al. ., 2009). Epping et al. (2005) showed 
that PRAME is a repressor of retinoic acid signaling but Steinbach et al. (2007) did not 
confirm this mechanism in the pathogenesis of AML. Specific immunotherapies for patients 
with AML using leukemia-associated antigens (LAA) as target structures might be a 
therapeutic option. Expression of genes for these antigens have prognostic importance 
(Greiner et al., 2008). 
AF1q (ALL1 fused gene from chromosome 1q) gene overexpression in CN-AML patients is 
associated with a significantly greater incidence of concurrent FLT3-ITD and with a poor 
outcome (Strunk et al., 2009). NC-AML patients with low AF1q expression had better overall 
survival and complete remission rate than patients with high AF1q mRNA level.  
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High MLL5 (mixed lineage leukemia 5) expression is associated with a favorable outcome of 
CN-AML patients and enables identification of a significant proportion of patients with 
favorable prognosis that are not identified by other markers analyses (Damm et al., 2011). 
Increased expression of the phosphoinositide phospholipase Cǃ1 (PI-PLC ┚1) gene is an 
independent prognostic factor in CN-AML and is associated with a significantly shorter 
overall survival but with no difference for relapse-free survival (Damm et al., 2010).  
The Rho family of small GTPases, including Rho, Rac and Cdc42, functions as critical 
mediators of signaling pathways from plasma membrane regulating actin assembly, 
migration, proliferation and survival in hematopoietic cells. RhoH gene, also known as 
Translocation Three Four (TTF), encodes a 191-amino acid protein belonging to the Rho 
family (Gu et al., 2005; Iwasaki et al., 2008). Rho H functions as a negative regulator for 
interleukin 3 (IL3) – induced signals through modulation of the JAK-STAT (Janus Kinase-
Signal Transducer and Activator of Transcription)- signaling pathway (Gűndogdu et al., 
2010). Low RhoH levels are connected with an upregulation of IL3- dependent cell growth, 
STAT5 activity and an increase of CD123 surface expression that has been described in AML 
patients (Gűndogdu et al., 2010). Multivariate analysis demonstrated that low expression of 
RhoH was an independent unfavorable prognostic factor for both overall and disease-free 
survival of AML in the intermediate risk group (Iwasaki et al., 2008).  
Activation of Notch signal pathway (expression of Notch1, Jagged1 and Delta1 as members of 
this pathway) is associated with a poorer prognosis for AML patients with intermediate risk 
(Xu et al., 2010). 
The Forkhead transcription factors (FOXO) are direct target of the PI3K/AKT (protein 
kinase B) signaling and they integrate the signals of several other transduction pathways at 
the transcriptional level. The PI3K/AKT/FOXO signaling pathway is up-regulated in AML.  
High FOXO3a expression is associated with a poorer prognosis in CN-AML (Santamaria et 
al., 2009) and the increased levels of both total and of highly phosphorylated FOXO3a 
correlate with higher proliferation and blood blasts  and  these high levels of FOXO3a are an 
adverse prognostic factor in AML (Kornblau et al., 2010).  
Bone marrow neoangiogenesis plays an important pathogenetic and possible prognostic role 
in AML (Hou et al., 2008; Lee et al., 2007; Loges et al., 2005; Mourah et al. 2009). 
Multivariable analysis showed that the levels of vascular endothelial growth factor (VEGF) 
transcript isoform 121 (VEGF121) remained an independent prognostic factor for either 
event-free survivasl or overall survival (Mourah et al., 2009). High levels of VEGF121 were 
significantly related to a worse prognosis. Angiopoietin-2  (Ang2) gene expression 
represents also an independent prognostic factor in AML with intermediate risk and high 
Ang2 expression is associated with an unfavorable prognosis (Hou et al., 2008; Lee et al., 
2007; Loges et al., 2005). High VEGFC expression appeared strongly associated with reduced 
complete remission rate, reduced overall and event-free survival in adult AML independent 
of cytogenetic risk and white blood cell count (de Jonge et al., 2010). High VEGFC 
expression was related to enhanced chemoresistance and predicted adverse long-term 
prognosis. 
TGFǃ (transforming growth factor beta) superfamily receptors ALK-1 (activin receptor like 
kinase) and ALK-5 have an important role in endothelial cells behavior and might be 
involved in the pathogenesis of AML. ALK-1 and ALK-5 are both expressed by the majority 
of AML patients. ALK-5 expression has a significant negative impact on complete remission 
achievment and overall survival of AML patients (Otten et al., 2011). 
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Dysregulation of the Wnt/ǃ-catenin pathway has been observed in various malignancies, 
including AML. Overexpression of ǃ-catenin is an independent adverse prognostic factor in 
AML (Chen et al., 2009; Ysebaert et al., 2006). 
Chemokine  (C-X-C motif) receptor 4 (CXCR4) retains hematopoietic progenitors and 
leukemia cells within the marrow microenvironment. Multivariate analysis revealed CXCR4 
expression as an independent prognostic factor for disease relapse and survival (Konoplev 
et al., 2007; Spoo et al., 2007; Tavernier-Tardy et al., 2009). Low CXCR4 expression correlated 
with a better prognosis, resulting in a longer relapse-free and overall survival. 
Many studies of AML have linked the overexpression of ABCB1 (also named permeability 
glycoprotein, Pgp), a member of ATP-binding proteins coded by the multi-drug resistance 
gene (MDR1), to poor prognosis (Leith et al., 1997; Steinbach & Legrand, 2007; Trnkova et 
al., 2007).  Other drug-resistance proteins BCRP (breast cancer resistance protein, also 
named ABCG2) and LRP (lung resistance protein) have also an adverse impact  (Dimiani et 
al., 2010; Huh et al., 2006).  
5. Gene expression profiling in CN-AML 
Gene expression profiling (GEP) was described twelve years ago by Golub et al. (1999). GEP 
analyses on the basis of microarrays allow the simultaneous characterization of thousands of 
genes. GEP is useful for the classification of leukemias. In CN-AML, microarray GEP has 
been applied to identify expression signatures in order  to predict clinical outcome within 
this very heterogeneous group of patients.  
Bullinger et al. (2004) and Radmacher et al. (2006) defined by GEP two novel molecular 
subclasses of CN-AML with significant differences in survival times with respect to the 
presence or absence of FLT3 mutations and the FAB subtypes.  
NPM1 gene mutations are connected with specific gene expression pattern in CN-AML 
(Alcalay et al., 2005; Becker et al., 2010; Garzon et al., 2008; Verhaak et al., 2005; Wilson et al., 
2006). This specific gene expression signature was characterised by the activation of homeobox 
(HOX) genes including a particular subset of homeobox TALE (three amino acid loop 
extension) genes distinguish themselves from typical homeodomains containing genes. 
Downregulated in the NPM1 mutations group were genes whose low expression is associated 
with better prognosis in CN-AML as BAALC, MN1, ERG, and multidrug resistance genes. 
Comparison of gene expression between biallelic CEBPA mutation and monoallelic CEBPA 
mutation AML was described by Dufour et al. (2010). Expression of multiple members of the 
homeobox gene family (HOXA5, HOXA9, HOXA10, HOXB2, and HOXB6), CD34, and 
lymphoid markers CD6, CD52, and TSPO (gene for translocator protein, benzodiazepine 
receptor) is downregulated in CN-AML patients with biallelic CEBPA mutation. 
Specific gene expression signatures associated with FLT3-ITD and FLT3-TKD (mutations in 
the tyrosine kinase domain)  were described (Bullinger et al., 2008; Neben et al., 2005; 
Whitman et al., 2008b, 2010). Overexpression of FLT3, homeobox genes (HOXB3, HOXB5, 
PBX3, MEIS1), and immunotherapeutic targets (WT1, CD33) and underexpression of 
leukemia associated (MLLT3, TAL1) and erythropoiesis-associated genes (GATA3, EPOR, 
ANK1, HEMGN) is typical for  FLT3-ITD, whereas overexpression of gene for transcription 
factor FOXA1 containing forkhead box was observed in FLT3-TKD (Neben et al., 2005, 
Whitman et al., 2010). Whereas the predictive value for FLT3-ITD was relatively high (77%), 
the high number of false predictions eliminates GEP as an investigational tool for research 
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studies  waiting on an entrance to clinical practice and decision making (Marcucci et al., 
2011a; Verhaak et al., 2009; Wouters et al., 2009). GEP technique seems not to be in future a 
primary diagnostic tool but will be used in many cases as a confirmative method. 
6. MicroRNA expression profiling 
MicroRNAs (miRs) are small noncoding RNAs of 19 to 25 nucleotides which function as 
negative regulators of gene expression by causing target mRNA cleavage or by interfering 
with target mRNA translation. Dysregulation of miRs plays an important role in the 
pathogenesis of many cancers based on their involvement in basic cellular functions (Nana-
Sinkam & Croce, 2010). In addition, miRs have the capacity to target tens to hundreds of 
genes simultaneously. Thus, they are attractive candidates as prognostic biomarkers and 
therapeutic targets in cancer. 
MiR expression signatures have been correlated with recurrent molecular aberrations in AML. 
NPM1 mutations associate with upregulation of miR10a, miR10b, and miR196a, all lying in the 
genomic cluster of HOX genes that are overexpressed (Becker et al., 2010, Garzon et al., 2008). 
Upregulation of miR181a and miR181b  expression is associated with  CEBPA mutations in CN-
AML (Marcucci et al., 2008; 2009; 2011b). FLT3-ITD was observed to be associated with miR155 
upregulation and miR144 and miR451 downregulation (Whitman et al., 2010). Genome-wide 
profiling identified aberrantly expressed miR associated with R172 IDH2 mutated CN-AML 
patients (Marcucci et al., 2010). The most upregulated miR genes were genes of miR125 family 
(miR125a and miR125b), miR1 and miR133. The most downregulated miR genes were miR194-1, 
miR526, miR520a-3p, and miR548b.  
Recent studies have also shown that clinical outcome in CN-AML is affected by changes in 
miR expression. Overexpression of miR20a, miR25, miR191, miR199a and miR199b adversely 
affected overall survival (Garzon et al., 2008).  
7. DNA methylation arrays 
DNA cytosine methylation in CpG islands regulates gene expression. Aberrant methylation 
of specific genes was observed in cancer including leukemia, although little is known about 
the mechanisms of this specific gene sets methylation. Genome-wide promoter DNA 
methylation profiling revealed unique AML subgroups and methylation patterns that are 
associated with clinical outcome (Bullinger & Armstrong, 2010; Figueroa et al., 2010). DNA 
methylation profiles segregates patients with CEBPA mutations from other subtypes of 
leukemia and defined four epigenetically distinct forms of AML with NPM1 mutations. 
Epigenetic modification of the CEBPA promoter regions was also described and CEBPA 
hypermethylation appeared to be favorable prognostic marker in addition to NPM1  
mutation with lack of FLT3-ITD and CEBPA bi-allelic, double mutations (Hackanson et al., 
2008; Lin et al., 2010; Szankasi et al., 2011). Lugthart et al. (2011) found that the promoter 
DNA methylation signature of EVI1 AML blast cells differed from normal bone marrow 
cells and other AMLs and contained many hypermethylated genes. EVI1 was observed to 
physically interact with DNA methyltransferases 3A and 3B and colocalize with them in 
nuclei and complex is involved in EVI1-mediated transcriptional repression.  Cases with the 
significantly higher levels of EVI1 are associated with many more methylated genes 
(Lugthart et al., 2011).  
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8. Conclusion and future directions 
CN-AML is very heterogeneous on the molecular level and harbours many genetic 
alterations that define new molecular subgroups. This molecular heterogeneity of CN-AML 
is not fully reflected in current classification systems (Vardiman et al. 2008, Döhner et al., 
2010). Molecular markers with prognostic significance are very important  for future 
therapies. Decision over whether to allograft a patient in first complete remission depends 
on the evaluation in a risk/benefit analysis in prognostic scoring system (Smith et al., 2011). 
The favorable cytogenetic risk group is now supplemented by CN-AML with mutant NPM1 
or  biallelic CEBPA mutations in the absence of FLT3-ITD (Döhner et al., 2010). These CN-
AML patients may not need to be referred for allogenic stem cell transplantation in first 
complete remission (Burnett et al., 2011). Low expression of BAALC is also associated with 
favorable outcome in CN-AML (Santamaria et al., 2010), but not  in association with FLT3, 
NPM1, and CEBPA mutations and may not be prognostic in older patients (Langer et al., 
2008). Low BAALC expression is an important factor for complete remission achievment and 
longer disease-free survival. Even better overall survival is reached in CN-AML patients 
who had low ERG expression in addition to low BAALC expression (Burnett et al., 2011). 
The similarity of BAALC  and ERG expression signatures  between younger and older CN-
AML patients and the fact that these molecular markers affect similarly outcomes in the 
group of younger and older than 60 years CN-AML patients sugest that older patients with 
favorable molecular risk factors, such as low BAALC  and ERG expression , if treated more 
intensively, might have outcomes comparable with  those of younger CN-AML patients 
with the same molecular markers (Schwind et al., 2010). Patients with low ERG, low EVI1, 
and high PRAME expression levels were also shown to have a good prognosis (Santamaria 
et al., 2009). Recently, Damm et al. (2011) proposed an integrative prognostic risk score 
(IPRS) for CN-AML patients based on clinical and molecular markers. Nine clinical, 
hematological and molecular factors including age, white blood cell count, mutation status 
of NPM1, FLT3-ITD, CEBPA, WT1 single nucleotide polymorphism SNP rs16754, and 
expression levels of BAALC, ERG, MN1, and WT1 (Damm et al., 2011). Other molecular 
markers like NRAS, MLL-PTD, WT1, IDH1, or IDH2 mutations were not significant and thus 
not included in the IPRS. 
Genomewide search and new technologies will help to subcategorize CN-AML. Gene and 
microRNA signatures and DNA methylation signatures obtained in these studies may 
detect potential targets for new therapies.  
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